
|Articles|April 16, 2007
Valve risk leads to withdrawal of pergolide (Permax, Valiant)
Two high-quality reports in the New England Journal of Medicine confirming the risk of valvulopathy with the use of pergolide (Permax, Valiant) have led the FDA to remove the drug from the U.S. market. Two generic forms of the drug, made by Teva and Par Pharmaceuticals, will also be withdrawn.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Bipartisan Legislation Aims to Address Consolidation and Vertical Integration of PBMs
2
FDA Reaffirms Strict Regulations Amid GLP-1 Compounding Concerns
3
FDA Removes Black Box Warning on 6 Menopausal Hormone Therapy Products
4
Tryptyr Increases Tear Production in Dry Eye Disease
5




































